TCGA-A7-A26G-01A-21R-A169-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.460
- PROTEIN_SECRETION+0.450
- KRAS_SIGNALING_UP+0.420
- INFLAMMATORY_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.360
- ALLOGRAFT_REJECTION+0.350
- UV_RESPONSE_DN+0.350
- COMPLEMENT+0.340
- HEDGEHOG_SIGNALING+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.420
- ESTROGEN_RESPONSE_LATE-0.370
- ESTROGEN_RESPONSE_EARLY-0.360
- DNA_REPAIR-0.290
- INTERFERON_ALPHA_RESPONSE-0.250
- FATTY_ACID_METABOLISM-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- MYOGENESIS-0.140
- MYC_TARGETS_V1-0.120
- KRAS_SIGNALING_DN-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.851 |
| 2 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.836 |
| 3 | SAMN03290934 | — | — | 0.832 |
| 4 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.821 |
| 5 | DRR168609 | — | — | 0.818 |
| 6 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.799 |
| 7 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.796 |
| 8 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.790 |
| 9 | TCGA-A8-A08Z-01A-21R-A00Z-07 | — | A | 0.787 |
| 10 | SRR15030887 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |